WEPOG
VRTX icon

Wealth Enhancement & Preservation of GA’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealth Enhancement & Preservation of GA’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6,251
Closed -$1.8M – 55
2020
Q2 		$1.8M Buy
+6,251
New +$1.69M 2.24% 14

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wealth Enhancement & Preservation of GA's VRTX Position: Q3 2020 in Review

Wealth Enhancement & Preservation of GA sold out of Vertex Pharmaceuticals (VRTX) in Q3 2020, closing a stake of 6,251 shares — an estimated $1.8M sold.

Wealth Enhancement & Preservation of GA first reported a position in VRTX in Q2 2020 and held it in 1 quarter. The position peaked at $1.8M in Q2 2020. 951 funds tracked by Wall St. Rank hold VRTX as of Q3 2020.

  • Wealth Enhancement & Preservation of GA reported no remaining Vertex Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Wealth Enhancement & Preservation of GA sold 6,251 Vertex Pharmaceuticals shares in Q3 2020, an estimated $1.8M.
  • Wealth Enhancement & Preservation of GA first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Wealth Enhancement & Preservation of GA's Vertex Pharmaceuticals position peaked at $1.8M in Q2 2020.
  • 951 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2020.

Based on Wealth Enhancement & Preservation of GA's 13F filing for Q3 2020, filed 13 Oct 2020.